Current and emerging strategies for the management of sarcoidosis

Bibliography

• LYNCH III JP, WHITE ES: Pulmonary Sarcoidosis. In: Sarcoidosis: Eur. Respir. Mon. Drent M and Costabel U (Eds), (2005) 32:105-129.
   Google Scholar
• HILLERDAL G, NOU E, OSTERMAN K, SCHMEKEL B: Sarcoidosis: epidemiology and prognosis. A 15-year European study. Am. Rev. Respir. Dis. (1984) 130(1):29-32.
   PubMed Web of Science ®Google Scholar
• HENKE C, HENKE G, ELVEBACK L, AL E: The epidemiology of sarcoidosis in Rochester, Minnesota: a population-based study of incidence and survival. Am. J. Epidemiol. (1986) 123:840-845.
   PubMed Web of Science ®Google Scholar
• NEVILLE E, WALKER A, JAMES DG: Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. Q. J. Med. (1983) 208:525-533.
   Google Scholar
• ROMER FK: Presentation of sarcoidosis and outcome of pulmonary changes. Dan. Med. Bull. (1982) 29(1):27-32.
   PubMedGoogle Scholar
• SCADDING J: Prognosis of intrathoracic sarcoidosis in England: a review of 136 cases after five years' observation. Br. Med. J. (1961) 2:1165-1172.
   PubMed Web of Science ®Google Scholar
• PARAMOTHAYAN NS, LASSERSON TJ, JONES PW: Corticosteroids for pulmonary sarcoidosis. Cochrane Database Syst. Rev. (2005) 2:CD001114.
   Google Scholar
• GOTTLIEB JE, ISRAEL HL, STEINER RM, TRIOLO J, PATRICK H: Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. Chest (1997) 111(3):623-631.
   PubMed Web of Science ®Google Scholar
• JOHNS CJ, SCHONFELD SA, SCOTT PP, ZACHARY JB, MACGREGOR MI: Longitudinal study of chronic sarcoidosis with low-dose maintenance corticosteroid therapy. Outcome and complications. Ann. NY Acad. Sci. (1986) 465:702-712.
   PubMed Web of Science ®Google Scholar
• SEMENZATO G, BORTOLI M, BRUNETTA E, AGOSTINI C: Immunology and pathophysiology. Eur. Resp. Mon. (2005) 32:49-63.
   Google Scholar
• GIBEJOVA A, MRAZEK F, SUBRTOVA D et al.: Expression of macrophage inflammatory protein-3β/CCL19 in pulmonary sarcoidosis. Am. J. Respir. Crit. Care Med. (2003) 167(12):1695-1703.
   PubMed Web of Science ®Google Scholar
• VENET A, SANDRON D, ISRAEL-BIET D: Bronchoalveolar lavage in interstitial lung diseases. Bull. Eur. Physiopathol. Respir. (1985) 21(6):465-476.
   PubMedGoogle Scholar
• STRIDH H, PLANCK A, GIGLIOTTI D, EKLUND A, GRUNEWALD J: Apoptosis resistant bronchoalveolar lavage (BAL) fluid lymphocytes in sarcoidosis. Thorax (2002) 57(10):897-901.
   PubMed Web of Science ®Google Scholar
• SHIGEHARA K, SHIJUBO N, OHMICHI M et al.: Increased circulating interleukin-12 (IL-12) p40 in pulmonary sarcoidosis. Clin. Exp. Immunol. (2003) 132(1):152-157.
   PubMed Web of Science ®Google Scholar
• SHIGEHARA K, SHIJUBO N, OHMICHI M et al.: Enhanced mRNA expression of Th1 cytokines and IL-12 in active pulmonary sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis. (2000) 17(2):151-157.
   PubMed Web of Science ®Google Scholar
• SHIGEHARA K, SHIJUBO N, OHMICHI M et al.: IL-12 and IL-18 are increased and stimulate IFN-γ production in sarcoid lungs. J. Immunol. (2001) 166(1):642-649.
   PubMed Web of Science ®Google Scholar
• ROBINSON BW, MCLEMORE TL, CRYSTAL RG: Gamma interferon is spontaneously released by alveolar macrophages and lung T lymphocytes in patients with pulmonary sarcoidosis. J. Clin. Invest. (1985) 75(5):1488-1495.
   PubMed Web of Science ®Google Scholar
• MARZOUK K, SALEH S, KANNASS M, SHARMA OP: Interferon-induced granulomatous lung disease. Curr. Opin. Pulm. Med. (2004) 10(5):435-440.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI R, SHIJUBO N, SHIGEHARA K et al.: T helper 1 inhibitor TAK-603 inhibits IFN-gamma and IL-12 production with no effect on IL-18: an observation in sarcoidosis patients. Sarcoidosis Vasc. Diffuse Lung Dis. (2004) 21(3):204-211.
   PubMed Web of Science ®Google Scholar
• ROACH DR, BEAN AG, DEMANGEL C et al.: TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J. Immunol. (2002) 168(9):4620-4627.
   PubMed Web of Science ®Google Scholar
• LUKACS NW, CHENSUE SW, STRIETER RM, WARMINGTON K, KUNKEL SL: Inflammatory granuloma formation is mediated by TNF-α-inducible intercellular adhesion molecule-1. J. Immunol. (1994) 152(12):5883-5889.
   PubMed Web of Science ®Google Scholar
• MYATT N, COGHILL G, MORRISON K, JONES D, CREE IA: Detection of tumour necrosis factor α in sarcoidosis and tuberculosis granulomas using in situ hybridisation. J. Clin. Pathol. (1994) 47(5):423-426.
   PubMed Web of Science ®Google Scholar
• BELLI F, CAPRA A, MORAITI A, ROSSI S, ROSSI P: Cytokines assay in peripheral blood and bronchoalveolar lavage in the diagnosis and staging of pulmonary granulomatous diseases. Int. J. Immunopathol. Pharmacol. (2000) 13(2):61-67.
   PubMed Web of Science ®Google Scholar
• STEFFEN M, PETERSEN J, OLDIGS M et al.: Increased secretion of tumor necrosis factor-α, interleukin-1-β, and interleukin-6 by alveolar macrophages from patients with sarcoidosis. J. Allergy Clin. Immunol. (1993) 91(4):939-949.
   PubMed Web of Science ®Google Scholar
• ZIEGENHAGEN MW, BENNER UK, ZISSEL G et al.: Sarcoidosis: TNF-α release from alveolar macrophages and serum level of sIL-2R are prognostic markers. Am. J. Respir. Crit. Care Med. (1997) 156:1586-1592.
   PubMed Web of Science ®Google Scholar
• ZIEGENHAGEN MW, MULLER-QUERNHEIM J: The cytokine network in sarcoidosis and its clinical relevance. J. Intern. Med. (2003) 253(1):18-30.
   PubMed Web of Science ®Google Scholar
• THORN GW, FORSHAM PH, FRAWLEY TF et al.: Clinical usefulness of ACTH and cortisone. N. Eng. J. Med. (1950) 242:783-793, 824-834, 865-872.
   PubMed Web of Science ®Google Scholar
• SILTZBACH LE: Effect of cortisone in sarcoidosis: a study of 13 patients. Am. J. Med. (1952) 12:139-160.
   PubMed Web of Science ®Google Scholar
• SONES M, ISRAEL HL, DRATMAN MB, FRANK JH: Effect of cortisone in sarcoidosis. N. Eng. J. Med. (1951) 244:209-213.
   PubMed Web of Science ®Google Scholar
• EMIRGIL C, SOBOL BJ, WILLIAMS MH, Jr.: Long-term study of pulmonary sarcoidosis. The effect of steroid therapy as evaluated by pulmonary function studies. J. Chronic. Dis. (1969) 22(2):69-86.
   PubMedGoogle Scholar
• BAUGHMAN RP, SHARMA OP, LYNCH JP, III: Sarcoidosis: is therapy effective? Semin. Respir. Infect. (1998) 13(3):255-273.
   PubMedGoogle Scholar
• LYNCH III JP, STRIETER RM: Sarcoidosis. In: Immunologically Mediated Pulmonary Disorders. Lynch JP, III, DeRemee RA (Eds), JB Lippincott, Philadelphia, PA (1991):189-216.
   Google Scholar
• COSTABEL U: Sarcoidosis: clinical update. Eur. Respir. J. (2001) 18(Suppl. 32):56s-68s.
   Google Scholar
• Statement on sarcoidosis. Am. J. Respir. Crit. Care Med. (1999) 160(2):736-755.
   PubMed Web of Science ®Google Scholar
• STONE DJ, SCHWARTZ A: A long-term study of sarcoid and its modification by steroid therapy. Lung function and other factors in prognosis. Am. J. Med. (1966) 41(4):528-540.
   PubMed Web of Science ®Google Scholar
• SHARMA OP, COLP C, WILLIAMS MH: Course of pulmonary sarcoidosis with and without corticosteroid therapy as determined by pulmonary function studies. Am. J. Med. (1966) 41:541-551.
   PubMed Web of Science ®Google Scholar
• HOYLE C, SMYLLIE H, LEAK D: Prolonged treatment of pulmonary sarcoidosis with corticosteroids. Thorax (1967) 22:519-524.
   PubMed Web of Science ®Google Scholar
• GIBSON GJ, PRESCOTT RJ, MUERS MF et al.: British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment. Thorax (1996) 51(3):238-247.
   PubMed Web of Science ®Google Scholar
• HARKLEROAD LE, YOUNG RL, SAVAGE PJ, JENKINS DW, LORDON RE: Pulmonary sarcoidosis. Long-term follow-up of the effects of steroid therapy. Chest (1982) 82(1):84-87.
   PubMed Web of Science ®Google Scholar
• ALBERTS C, VAN DER MARK T, JANSEN H: Inhaled budesonide in pulmonary sarcoidosis: a double-blind, placebo-controlled study. Dutch Study Group on Pulmonary Sarcoidosis. Eur. Respir. J. (1995) 8:682-688.
   PubMed Web of Science ®Google Scholar
• SELROOS OB: Use of budesonide in the treatment of pulmonary sarcoidosis. Ann. NY Acad. Sci. (1986) 465:713-721.
   PubMed Web of Science ®Google Scholar
• SPITERI M: Inhaled corticosteroids in pulmonary sarcoidosis. Postgrad. Med. (1991) 67:237-329.
   Google Scholar
• SPITERI M, NEWMAN S, CLARKE S, PAULTER L: Inhaled corticosteroids can modulate the immunopathogenesis of pulmonary sarcoidosis. Eur. Respir. J. (1989) 2:218-224.
   PubMed Web of Science ®Google Scholar
• ERKKILA S, FROSETH B, HELLSTROM PE et al.: Inhaled budesonide influences cellular and biochemical abnormalities in pulmonary sarcoidosis. Sarcoidosis (1988) 5(2):106-110.
   PubMedGoogle Scholar
• MILMAN N, GRAUDAL N, GRODE G, MUNCH E: No effect of high-dose inhaled steroids in pulmonary sarcoidosis: a double-blind, placebo-controlled study. J. Intern. Med. (1994) 236(3):285-290.
   PubMed Web of Science ®Google Scholar
• BAUGHMAN RP, IANNUZZI MC, LOWER EE et al.: Use of fluticasone in acute symptomatic pulmonary sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis. (2002) 19(3):198-204.
   PubMed Web of Science ®Google Scholar
• DU BOIS RM, GREENHALGH PM, SOUTHCOTT AM, JOHNSON NM, HARRIS TA: Randomized trial of inhaled fluticasone propionate in chronic stable pulmonary sarcoidosis: a pilot study. Eur. Respir. J. (1999) 13(6):1345-1350.
   PubMed Web of Science ®Google Scholar
• LOWER EE, BAUGHMAN RP: Prolonged use of methotrexate for sarcoidosis. Arch. Intern. Med. (1995) 155(8):846-851.
   PubMedGoogle Scholar
• WEBSTER G, RAZSI L, SANCHEZ M, SHUPACK J: Weekly low-dose methotrexate therapy for cutaneous sarcoidosis. J. Am. Acad. Dermatol. (1991) 24:451-454.
   PubMed Web of Science ®Google Scholar
• DEV S, MCCALLUM RM, JAFFE GJ: Methotrexate treatment for sarcoid-associated panuveitis. Ophthalmology (1999) 106(1):111-118.
   PubMed Web of Science ®Google Scholar
• LOWER EE, BRODERICK JP, BROTT TG, BAUGHMAN RP: Diagnosis and management of neurological sarcoidosis. Arch. Intern. Med. (1997) 157(16):1864-1868.
   PubMed Web of Science ®Google Scholar
• KAYE O, PALAZZO E, GROSSIN M et al.: Low-dose methotrexate: an effective corticosteroid-sparing agent in the musculoskeletal manifestations of sarcoidosis. Br. J. Rheumatol. (1995) 34(7):642-644.
   PubMedGoogle Scholar
• BAUGHMAN RP, WINGET DB, LOWER EE: Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc. Diffuse Lung Dis. (2000) 17:60-66.
   PubMed Web of Science ®Google Scholar
• BAUGHMAN RP, LOWER EE: The effect of corticosteroid or methotrexate therapy on lung lymphocytes and macrophages in sarcoidosis. Am. Rev. Respir. Dis. (1990) 142(6 Pt 1):1268-1271.
   PubMedGoogle Scholar
• MORGAN SL, BAGGOTT JE, VAUGHN WH et al.: Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann. Intern. Med. (1994) 121(11):833-841.
   PubMed Web of Science ®Google Scholar
• AITHAL GP, HAUGK B, DAS S et al.: Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified? Aliment. Pharmacol. Ther. (2004) 19(4):391-399.
   PubMed Web of Science ®Google Scholar
• CHALMERS RJ, KIRBY B, SMITH et al.: Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis. Br. J. Dermatol. (2005) 152(3):444-450.
   PubMed Web of Science ®Google Scholar
• IMOKAWA S, COLBY TV, LESLIE KO, HELMERS RA: Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur. Respir. J. (2000) 15(2):373-381.
   PubMed Web of Science ®Google Scholar
• NEWSOME G: Guidelines for the management of rheumatoid arthritis: 2002 update. J. Am. Acad. Nurse Pract. (2002) 14(10):432-437.
   PubMedGoogle Scholar
• ZIEGLER HK, UNANUE ER: Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells. PNAS (1982) 79(1):175-178.
   PubMed Web of Science ®Google Scholar
• JEONG JY, JUE DM: Chloroquine inhibits processing of tumor necrosis factor in lipopolysaccharide-stimulated RAW 264.7 macrophages. J. Immunol. (1997) 158(10):4901-4907.
   PubMed Web of Science ®Google Scholar
• JANG CH, CHOI JH, BYUN MS, JUE DM: Chloroquine inhibits production of TNF-{α}, IL-1{β} and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes. Rheumatology (2006) 45(6):703-710.
   PubMed Web of Science ®Google Scholar
• BALTZAN M, MEHTA S, KIRKHAM TH, COSIO MG: Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am. J. Respir. Crit. Care Med. (1999) 160(1):192-197.
   PubMed Web of Science ®Google Scholar
• O'LEARY TJ, JONES G, YIP A et al.: The effects of chloroquine on serum 1,25-dihydroxyvitamin D and calcium metabolism in sarcoidosis. N. Engl. J. Med. (1986) 315(12):727-730.
   PubMed Web of Science ®Google Scholar
• SILTZBACH L, TIERSTEIN A: Chloroquine therapy in 43 patients with intrathoracic and cutaneous sarcoidosis. Acta Med. Scand. (1964) 425:302-308.
   Google Scholar
• SHARMA OP: Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurological involvement. Arch. Neurol. (1998) 55(9):1248-1254.
   PubMed Web of Science ®Google Scholar
• SHIMONI A, HERSHCOVICI T, MEKHMANDAROV S, MAOR-KENDLER Y, BEIGEL Y: Skeletal sarcoidosis: successful treatment with hydroxychloroquine. Isr. Med. Assoc. J. (2000) 2(7):558-559.
   PubMed Web of Science ®Google Scholar
• JONES E, CALLEN JP: Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas. J. Am. Acad. Dermatol. (1990) 23(3 Pt 1):487-489.
   PubMed Web of Science ®Google Scholar
• QUATRARO A, CONSOLI G, MAGNO M et al.: Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus. A new job for an old drug? Ann. Intern. Med. (1990) 112(9):678-681.
   PubMed Web of Science ®Google Scholar
• MORSE SI, COHN ZA, HIRSCH JG, SCHAEDER RW: The treatment of sarcoidosis with chloroquine. Am. J. Med. (1961) 30:779-784.
   PubMed Web of Science ®Google Scholar
• DAVIES D: Sarcoidosis treated with chloroquine. Br. J. Dis. Chest (1963) 57:30-36.
   PubMedGoogle Scholar
• DESIMONE DP, BRILLIANT HL, BASILE J et al.: Granulomatous infiltration of the talus and abnormal vitamin D and calcium metabolism in a patient with sarcoidosis: successful treatment with hydroxychloroquine. Am. J. Med. (1989) 87:694-696.
   PubMed Web of Science ®Google Scholar
• ALLANORE Y, PERROT S, MENKES CJ, KAHAN A: Management of a patient with sarcoid calcaneitis and dactylitis. Joint Bone Spine (2001) 68(2):175-177.
   PubMed Web of Science ®Google Scholar
• BERNSTEIN HN: Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy. Am. J. Med. (1983) 75(1A):25-34.
   PubMed Web of Science ®Google Scholar
• MARMOR MF, CARR RE, EASTERBROOK M, FARJO AA, MIELER WF: Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology (2002) 109(7):1377-1382.
   PubMed Web of Science ®Google Scholar
• DEMETER S: Myocardial sarcoidosis unresponsive to steroids. Treatment with cyclophosphamide. Chest (1988) 94:202-203.
   PubMed Web of Science ®Google Scholar
• DOTY JD, MAZUR JE, JUDSON MA: Treatment of corticosteroid-resistant neurosarcoidosis with a short-course cyclophosphamide regimen. Chest (2003) 124(5):2023-2026.
   PubMed Web of Science ®Google Scholar
• TALAR-WILLIAMS C, HIJAZI Y, WALTHER M et al.: Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann. Intern. Med. (1996) 124:477-484.
   PubMed Web of Science ®Google Scholar
• WHITE ES, LYNCH JP: Pharmacological therapy for Wegener's granulomatosis. Drugs (2006) 66(9):1209-1228.
   PubMed Web of Science ®Google Scholar
• MULLER-QUERNHEIM J, KIENAST K, HELD M, PFEIFER S, COSTABEL U: Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur. Respir. J. (1999) 14(5):1117-1122.
   PubMed Web of Science ®Google Scholar
• PACHECO Y, MARECHAL C, MARECHAL F, BIOT N, PERRIN FAYOLLE M: Azathioprine treatment of chronic pulmonary sarcoidosis. Sarcoidosis (1985) 2(2):107-113.
   PubMedGoogle Scholar
• AGBOGU BN, STERN BJ, SEWELL C, YANG G: Therapeutic considerations in patients with refractory neurosarcoidosis. Arch. Neurol. (1995) 52(9):875-879.
   PubMed Web of Science ®Google Scholar
• AYYALA US, PADILLA ML: Diagnosis and treatment of hepatic sarcoidosis. Curr. Treat. Options Gastroenterol. (2006) 9(6):475-483.
   PubMedGoogle Scholar
• KENNEDY PT, ZAKARIA N, MODAWI SB et al.: Natural history of hepatic sarcoidosis and its response to treatment. Eur. J. Gastroenterol. Hepatol. (2006) 18(7):721-726.
   PubMed Web of Science ®Google Scholar
• LEWIS SJ, AINSLIE GM, BATEMAN ED: Efficacy of azathioprine as second-line treatment in pulmonary sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis. (1999) 16(1):87-92.
   PubMed Web of Science ®Google Scholar
• SHERLOCK S: The spectrum of hepatotoxicity due to drugs. Lancet (1986) 2(8504):440-444.
   PubMed Web of Science ®Google Scholar
• CONNELL WR, KAMM MA, DICKSON M et al.: Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet (1994) 343(8908):1249-1252.
   PubMed Web of Science ®Google Scholar
• EICHELBAUM M, INGELMAN-SUNDBERG M, EVANS WE: Pharmacogenomics and individualized drug therapy. Annu. Rev. Med. (2006) 57(1):119-137.
   PubMed Web of Science ®Google Scholar
• ROBERTS SD, WILKES DS, BURGETT RA, KNOX KS: Refractory sarcoidosis responding to infliximab. Chest (2003) 124(5):2028-2031.
   PubMed Web of Science ®Google Scholar
• MORCOS Z: Refractory neurosarcoidosis responding to infliximab. Neurology (2003) 60(7):1220-1221; author reply 1220-1221.
   PubMedGoogle Scholar
• PETTERSEN JA, ZOCHODNE DW, BELL RB, MARTIN L, HILL MD: Refractory neurosarcoidosis responding to infliximab. Neurology (2002) 59(10):1660-1661.
   PubMed Web of Science ®Google Scholar
• HOITSMA E, FABER CG, VAN SANTEN-HOEUFFT M et al.: Improvement of small fiber neuropathy in a sarcoidosis patient after treatment with infliximab. Sarcoidosis Vasc. Diffuse Lung Dis. (2006) 23(1):73-77.
   PubMed Web of Science ®Google Scholar
• MEYERLE JH, SHORR A: The use of infliximab in cutaneous sarcoidosis. J. Drugs Dermatol. (2003) 2(4):413-414.
   PubMedGoogle Scholar
• YEE AM, POCHAPIN MB: Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-α therapy. Ann. Intern. Med. (2001) 135(1):27-31.
   PubMed Web of Science ®Google Scholar
• BAUGHMAN RP, DRENT M, KAVURU M et al.: Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am. J. Resp Crit. Care Med. (2006) 173(7):795-802.
   Google Scholar
• YE Q, CHEN B, TONG Z et al.: Thalidomide reduces IL-18, IL-8 and TNF-α release from alveolar macrophages in interstitial lung disease. Eur. Respir. J. (2006) 28(4):824-831.
   PubMed Web of Science ®Google Scholar
• ESTINES O, REVUZ J, WOLKENSTEIN P et al.: [Sarcoidosis: thalidomide treatment in ten patients]. Ann. Dermatol. Venereol. (2001) 128(5):611-613.
   PubMed Web of Science ®Google Scholar
• BAUGHMAN RP, JUDSON MA, TEIRSTEIN AS, MOLLER DR, LOWER EE: Thalidomide for chronic sarcoidosis. Chest (2002) 122(1):227-232.
   PubMed Web of Science ®Google Scholar
• NGUYEN YT, DUPUY A, CORDOLIANI F et al.: Treatment of cutaneous sarcoidosis with thalidomide. J. Am. Acad. Dermatol. (2004) 50(2):235-241.
   PubMed Web of Science ®Google Scholar
• JUDSON MA, SILVESTRI J, HARTUNG C, BYARS T, COX CE: The effect of thalidomide on corticosteroid-dependent pulmonary sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis. (2006) 23(1):51-57.
   PubMed Web of Science ®Google Scholar
• GUNZLER V: Thalidomide in human immunodeficiency virus (HIV) patients. A review of safety considerations. Drug Saf. (1992) 7(2):116-134.
   PubMed Web of Science ®Google Scholar
• BASTUJI-GARIN S, OCHONISKY S, BOUCHE P et al.: Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients. J. Invest. Dermatol. (2002) 119(5):1020-1026.
   PubMed Web of Science ®Google Scholar
• DOHERTY GM, JENSEN JC, ALEXANDER HR, BURESH CM, NORTON JA: Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery (1991) 110(2):192-198.
   PubMed Web of Science ®Google Scholar
• ZABEL P, ENTZIAN P, DALHOFF K, SCHLAAK M: Pentoxifylline in treatment of sarcoidosis. Am. J. Respir. Crit. Care Med. (1997) 155(5):1665-1669.
   PubMed Web of Science ®Google Scholar
• MARQUES LJ, ZHENG L, POULAKIS N, GUZMAN J, COSTABEL U: Pentoxifylline inhibits TNF-α production from human alveolar macrophages. Am. J. Respir. Crit. Care Med. (1999) 159(2):508-511.
   PubMed Web of Science ®Google Scholar
• TONG Z, DAI H, CHEN B et al.: Inhibition of cytokine release from alveolar macrophages in pulmonary sarcoidosis by pentoxifylline: comparison with dexamethasone. Chest (2003) 124(4):1526-1532.
   PubMed Web of Science ®Google Scholar
• MANGANIELLO VC, PARK MK, STYLIANOU M et al.: A randomized trial of pentoxifylline in pulmonary sarcoidosis. Proc. Am. Thorac. Soc. (2005) 2(Abstracts Issue):A18.
   Google Scholar
• RUCKEMANN K, FAIRBANKS LD, CARREY EA et al.: Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans. J. Biol. Chem. (1998) 273(34):21682-21691.
   PubMed Web of Science ®Google Scholar
• MAJITHIA V, SANDERS S, HARISDANGKUL V, WILSON JG: Successful treatment of sarcoidosis with leflunomide. Rheumatology (Oxford) (2003) 42(5):700-702.
   PubMed Web of Science ®Google Scholar
• BAUGHMAN RP, LOWER EE: Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis. (2004) 21(1):43-48.
   PubMed Web of Science ®Google Scholar
• NAKAMURA M, OGAWA N, SHALABI A et al.: Positive effect on T-cell regulatory apoptosis by mycophenolate mofetil. Clin. Transplant. (2001) (15 Suppl.) 6:36-40.
   Google Scholar
• COHN RG, MIRKOVICH A, DUNLAP B et al.: Mycophenolic acid increases apoptosis, lysosomes and lipid droplets in human lymphoid and monocytic cell lines. Transplantation (1999) 68(3):411-418.
   PubMed Web of Science ®Google Scholar
• KILMARTIN DJ, FORRESTER JV, DICK AD: Rescue therapy with mycophenolate mofetil in refractory uveitis. Lancet (1998) 352(9121):35-36.
   PubMed Web of Science ®Google Scholar
• KOUBA DJ, MIMOUNI D, RENCIC A, NOUSARI HC: Mycophenolate mofetil may serve as a steroid-sparing agent for sarcoidosis. Br. J. Dermatol. (2003) 148(1):147-148.
   PubMed Web of Science ®Google Scholar
• MOUDGIL A, PRZYGODZKI RM, KHER KK: Successful steroid-sparing treatment of renal limited sarcoidosis with mycophenolate mofetil. Pediatr. Nephrol. (2006) 21(2):281-285.
   PubMed Web of Science ®Google Scholar
• KATARIA YP: Chlorambucil in sarcoidosis. Chest (1980) 78(1):36-43.
   PubMed Web of Science ®Google Scholar
• ISRAEL HL, MCCOMB BL: Chlorambucil treatment of sarcoidosis. Sarcoidosis (1991) 8(1):35-41.
   PubMedGoogle Scholar
• MARTINET Y, PINKSTON P, SALTINI C et al.: Evaluation of the in vitro and in vivo effects of cyclosporine on the lung T-lymphocyte alveolitis of active pulmonary sarcoidosis. Am. Rev. Respir. Dis. (1988) 138(5):1242-1248.
   PubMed Web of Science ®Google Scholar
• AKPEK EK, ILHAN-SARAC O, GREEN WR: Topical cyclosporin in the treatment of chronic sarcoidosis of the conjunctiva. Arch. Ophthalmol. (2003) 121(9):1333-1335.
   PubMed Web of Science ®Google Scholar
• BIELORY L, HOLLAND C, GASCON P, FROHMAN L: Uveitis, cutaneous and neurosarcoid: treatment with low-dose cyclosporine A. Transplant. Proc. (1988) 20(3 Suppl 4):144-148.
   PubMed Web of Science ®Google Scholar
• KAVANAUGH AF, ANDREW SL, COOPER B, LAWRENCE EC, HUSTON DP: Cyclosporine therapy of central nervous system sarcoidosis. Am. J. Med. (1987) 82(2):387.
   PubMedGoogle Scholar
• O'CALLAGHAN CA, WELLS AU, LALVANI A et al.: Effective use of cyclosporin in sarcoidosis: a treatment strategy based on computed tomography scanning. Eur. Respir. J. (1994) 7(12):2255-2256.
   PubMed Web of Science ®Google Scholar
• PIA G, PASCALIS L, ARESU G, ROSETTI L, LEDDA MA: Evaluation of the efficacy and toxicity of the cyclosporine A-flucortolone-methotrexate combination in the treatment of sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis. (1996) 13(2):146-152.
   PubMed Web of Science ®Google Scholar
• STERN BJ, SCHONFELD SA, SEWELL C et al.: The treatment of neurosarcoidosis with cyclosporine. Arch. Neurol. (1992) 49(10):1065-1072.
   PubMed Web of Science ®Google Scholar
• YORK EL, KOVITHAVONGS T, MAN SF, REBUCK AS, SPROULE BJ: Cyclosporine and chronic sarcoidosis. Chest (1990) 98(4):1026-1029.
   PubMed Web of Science ®Google Scholar
• WYSER CP, VAN SCHALKWYK EM, ALHEIT B, BARDIN PG, JOUBERT JR: Treatment of progressive pulmonary sarcoidosis with cyclosporin A. A randomized controlled trial. Am. J. Respir. Crit. Care Med. (1997) 156(5):1371-1376.
   PubMed Web of Science ®Google Scholar
• BRUNS F, PRUEMER B, HAVERKAMP U, FISCHEDICK AR: Neurosarcoidosis: an unusual indication for radiotherapy. Br. J. Radiol. (2004) 77(921):777-779.
   PubMed Web of Science ®Google Scholar
• MENNINGER MD, AMDUR RJ, MARCUS RB, Jr.: Role of radiotherapy in the treatment of neurosarcoidosis. Am. J. Clin. Oncol. (2003) 26(4):e115-e118.
   Google Scholar
• FRIZZELL B, STITH M, JENRETTE J: Management of treatment-resistant cutaneous sarcoidosis with radiation. Am. J. Clin. Oncol. (2002) 25(6):573-575.
   PubMed Web of Science ®Google Scholar
• KANG S, SUH JH: Radiation therapy for neurosarcoidosis: report of three cases from a single institution. Radiat. Oncol. Investig. (1999) 7(5):309-312.
   PubMedGoogle Scholar
• STELZER KJ, THOMAS CR, Jr., BERGER MS et al.: Radiation therapy for sarcoid of the thalamus/posterior third ventricle: case report. Neurosurgery (1995) 36(6):1188-1191.
   PubMed Web of Science ®Google Scholar
• AHMAD K, KIM YH, SPITZER AR et al.: Total nodal radiation in progressive sarcoidosis. Case report. Am. J. Clin. Oncol. (1992) 15(4):311-313.
   PubMed Web of Science ®Google Scholar
• GARCIA-MONCO C, BERCIANO J: Sarcoid meningitis, high adenosine deaminase levels in CSF and results of cranial irradiation. J. Neurol. Neurosurg. Psychiatry (1988) 51(12):1594-1596.
   PubMedGoogle Scholar
• RUBINSTEIN I, GRAY TA, MOLDOFSKY H, HOFFSTEIN V: Neurosarcoidosis associated with hypersomnolence treated with corticosteroids and brain irradiation. Chest (1988) 94(1):205-206.
   PubMed Web of Science ®Google Scholar
• BEJAR JM, KERBY GR, ZIEGLER DK, FESTOFF BW: Treatment of central nervous system sarcoidosis with radiotherapy. Ann. Neurol. (1985) 18(2):258-260.
   PubMed Web of Science ®Google Scholar
• FEIBELMAN RY, HARMAN EM: Sarcoid meningoencephalitis treated with high-dosage steroids and radiation. Ann. Intern. Med. (1985) 102(1):136.
   PubMedGoogle Scholar
• FOGEL TD, WEISSBERG JB, DOBULAR K, KIRCHNER JA: Radiotherapy in sarcoidosis of the larynx: case report and review of the literature. Laryngoscope (1984) 94(9):1223-1225.
   PubMed Web of Science ®Google Scholar
• GRIZZANTI JN, KNAPP AB, SCHECTER AJ, WILLIAMS MH, Jr.: Treatment of sarcoid meningitis with radiotherapy. Am. J. Med. (1982) 73(4):605-608.
   PubMed Web of Science ®Google Scholar
• WHITTAKER M, ANDERSON CK, CLARK PB: Sarcoidosis of the penis treated by radiotherapy. Br. J. Urol. (1975) 47(3):325-330.
   PubMedGoogle Scholar
• SHETA A: Sarcoidosis of the lacrimal gland. Clinicopathological reports of two cases with successful deep X-ray therapy. Bull. Ophthalmol. Soc. Egypt (1971) 64(68):539-545.
   PubMedGoogle Scholar
• SIMAY A, SZABO A: [Unusual fibrosis of the lung caused by grid irradiation in Boeck's sarcoid]. Beitr Klin Erforsch Tuberk Lungenkr (1967) 135(2):111-115.
   PubMedGoogle Scholar
• CIRLA A, SADA E: [Regression of sarcoidosic hilo-mediastinal adenopathy after radiotherapy]. Minerva Radiol. (1965) 10(11):567-568.
   PubMedGoogle Scholar
• KHANNA D, LIEBLING MR, LOUIE JS: Etanercept ameliorates sarcoidosis arthritis and skin disease. J. Rheumatol. (2003) 30(8):1864-1867.
   PubMed Web of Science ®Google Scholar
• HOBBS K: Chronic sarcoid arthritis treated with intraarticular etanercept. Arthritis Rheum. (2005) 52(3):987-988.
   PubMedGoogle Scholar
• TUCHINDA C, WONG HK: Etanercept for chronic progressive cutaneous sarcoidosis. J. Drugs Dermatol. (2006) 5(6):538-540.
   PubMedGoogle Scholar
• UTZ JP, LIMPER AH, KALRA S et al.: Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest (2003) 124(1):177-185.
   PubMed Web of Science ®Google Scholar
• BAUGHMAN RP, LOWER EE, BRADLEY DA, RAYMOND LA, KAUFMAN A: Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest (2005) 128(2):1062-1047.
   PubMed Web of Science ®Google Scholar
• GONZALEZ-LOPEZ MA, BLANCO R, GONZALEZ-VELA MC, FERNANDEZ-LLACA H, RODRIGUEZ-VALVERDE V: Development of sarcoidosis during etanercept therapy. Arthritis Rheum. (2006) 55(5):817-820.
   PubMed Web of Science ®Google Scholar
• GOLDENBERG MM: Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. Clin. Ther. (1999) 21(1):75-87; discussion 71-72.
   PubMed Web of Science ®Google Scholar
• VAN DULLEMEN HM, VAN DEVENTER SJ, HOMMES DW et al.: Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology (1995) 109(1):129-135.
   PubMed Web of Science ®Google Scholar
• TARGAN SR, HANAUER SB, VAN DEVENTER SJ et al.: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. Crohn's Disease cA2 Study Group. N. Engl. J. Med. (1997) 337(15):1029-1035.
   PubMed Web of Science ®Google Scholar
• GREEN CM: Topical tacrolimus for the treatment of cutaneous sarcoidosis. Clin. Exp. Dermatol. (2007) (Epub).
   Google Scholar
• KATOH N, MIHARA H, YASUNO H: Cutaneous sarcoidosis successfully treated with topical tacrolimus. Br. J. Dermatol. (2002) 147(1):154-156.
   PubMed Web of Science ®Google Scholar
• KARRER S, ABELS C, WIMMERSHOFF MB, LANDTHALER M, SZEIMIES RM: Successful treatment of cutaneous sarcoidosis using topical photodynamic therapy. Arch. Dermatol. (2002) 138(5):581-584.
   PubMedGoogle Scholar
• JUDSON MA: Extrapulmonary sarcoidosis. Semin. Respir. Crit. Care Med. (2007) 28(1):83-101.
   PubMed Web of Science ®Google Scholar
• BOZZETTE SA, FINKELSTEIN DM, SPECTOR SA et al.: A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N. Engl. J. Med. (1995) 332(11):693-699.
   PubMed Web of Science ®Google Scholar
• SCHNEIDER MM, NIELSEN TL, NELSING S et al.: Efficacy and toxicity of two doses of trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus. Dutch AIDS Treatment Group. J. Infect. Dis. (1995) 171(6):1632-1636.
   PubMed Web of Science ®Google Scholar
• EL-SADR WM, LUSKIN-HAWK R, YURIK TM et al.: A randomized trial of daily and thrice-weekly trimethoprim-sulfamethoxazole for the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected persons. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). Clin. Infect. Dis. (1999) 29(4):775-783.
   PubMed Web of Science ®Google Scholar
• JOUNDY N, CARPENTIER S, LECLECH C et al.: [Favourable course of a pseudotumoral form of hepatic and splenic sarcoidosis under treatment with hydroxychloroquine and colchicine]. Gastroenterol. Clin. Biol. (1995) 19(12):1066-1068.
   PubMedGoogle Scholar